RxDoctor Payments Data

Dung Tran, MD

Family Medicine · Metairie, LANPI 1386644342

Payments from drug & device makers

$8,811in general payments, 2019–2025

Across 582 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Pfizer$934
  • Lilly USA, LLC$617
  • Novo Nordisk$465
  • Bayer$399
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,793100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,811 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,638
Medicare patients
74
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide410$508,650
MounjaroTirzepatide82$93,664
FarxigaDapagliflozin Propanediol42$58,850
ProliaDenosumab28$48,899
JanuviaSitagliptin Phosphate43$43,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$42,315
XareltoRivaroxaban43$39,597
EliquisApixaban26$36,395
LinzessLinaclotide36$33,139
Breo ElliptaFluticasone/Vilanterol40$29,196
RybelsusSemaglutide12$19,103
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl106$15,800
Nurtec OdtRimegepant Sulfate11$15,030
SymbicortBudesonide/Formoterol Fumarate40$13,133
GlyxambiEmpagliflozin/Linagliptin15$8,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$465$527,753422 claims
Lilly USA, LLCMounjaro$617$93,66482 claims
AstraZenecaFarxiga, Symbicort$327$71,98382 claims
GSKTrelegy Ellipta, Breo Ellipta$1,446$71,51294 claims
PfizerEliquis, Nurtec Odt$934$51,42537 claims
AmgenProlia$184$48,89928 claims
MerckJanuvia$164$43,52643 claims
Johnson & JohnsonXarelto$115$39,59743 claims
AbbVieLinzess$1,983$33,13936 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$15$17,440138 claims
Boehringer IngelheimGlyxambi, Spiriva Respimat$392$14,78226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →